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Expression of protein kinase C (PKC) subspecies was studied in various human leukemia-lymphoma cell lines. The PKC 
in most cell lines examined was resolved into two major fractions corresponding to type II @sequence) and type III 
(a-sequence) PKC of the rat brain. The amounts of these two subspecies greatly varied among the cell lines. Type I PKC 
(y-sequence) was expressed in none of the cell lines tested, but PKCs with undefined structures were frequently detected. 
The differential co-expression of several PKC subspecies i presumably related to the state of cell differentiation. 
Protein kinase C; Differentiation; (Human leukemia-lymphoma cell line) 
1. INTRODUCTION 
Protein kinase C is generally accepted to play a 
pivotal role in physiological cellular responses to 
external signals such as those related to growth pro- 
motion and cell differentiation (reviews [ 1,2]). 
Molecular cloning and biochemical analysis of this 
enzyme reveals PKC as a family of multiple 
subspecies that have similar but distinct structures 
[2]. Initially, four cDNA clones, (Y, PI, PI1 and y, 
were isolated, which appear to be conserved among 
various mammalian species [2]. PKC from the 
brain tissues is normally resolved into three frac- 
tions, type I, II and III, upon hydroxyapatite col- 
umn chromatography [3-51, which correspond to 
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the enzyme encoded by y-, 0 (PI plus PII)- and (Y- 
cDNA clone, respectively [4-61. Some of these 
PKC subspecies show tissue-specific expression 
[6-91 and different ontogenic profiles [9,10]. A 
number of different human leukemia-lymphoma 
cell lines have been established in suspension 
culture [ 1 l-141. The application of multiple 
marker analysis indicates that each cell line consists 
of a homogeneous and monoclonal population, 
and that the cells are arrested at a certain stage of 
differentiation representing distinct differentia- 
tion-associated phenotypes, whose characteristics 
are consistently stable during long-term main- 
tenance [14]. The expression of PKC subspecies in 
some of the human leukemia-lymphoma cell lines 
will be described herein. 
2. MATERIALS AND METHODS 
2.1, Cell lines 
The leukemia-lymphoma cell lines used are assigned to one of 
the following groups: T-cell leukemia-lymphoma, B-cell 
leukemia-lymphoma, non-T/non-B cell leukemia, myelomono- 
cytic leukemia and erythroleukemia cell lines [14]. The differen- 
tiation stages of T- and B-cell leukemia-lymphoma cell lines are 
subcategorized as described in [ll]. All cell lines were grown as 
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suspension culture in RPM1 1640 medium supplemented with fer B. Fractions of 1 ml each were collected. Rat brain PKC, a 
5% heat-inactivated fetal calf serum at 37°C in a humidified 5% mixture of type I, II and III, was purified as described in 141. 
COZ atmosphere, and cells in their exponential growth phase The enzyme was assayed with calf thymus Hl histone as 
were used. The cell lines studied are listed in table 1. substrate as specified earlier [4]. 
2.2. Purification and assay of PKC 2.3. Immunoblot analysis 
PKC in each cell line was partially purified under the condi- 
tions specified earlier [15,16]. Briefly, the supernatant of the 
cells (approx. 5 x 10’ cells) was applied to a DE-52 column 
(1 x 2.5 cm, Whatman) equilibrated with 20 mM Tris-HCI at pH 
7.5, containing 0.5 mM EGTA, 0.5 mM EDTA and 10 mM 
2-mercaptoethanol (buffer A). PKC was eluted from the column 
by 6 ml of buffer A containing 200 mM NaCl, and was applied 
to a packed hydroxyapatite column (0.78 x 10 cm, Koken Co., 
Ltd., Tokyo, Type S), which was connected to a Pharmacia 
FPLC system and equilibrated with 20 mM potassium 
phosphate buffer at pH 7.5, containing0.5 mM EGTA, 0.5 mM 
EDTA, 10% glycerol and 10 mM 2-mercaptoethanol (buffer B). 
PKC was eluted by application of an 84-ml inear concentration 
gradient of potassium phosphate (20-215 mM) prepared in buf- 
Immunoblot analysis was made as described previously [8]. 
The antibodies employed for the present studies were raised 
against synthetic oligopeptides which are parts of the deduced 
amino acid sequences of the PKC subspecies [7,8]. The antibody 
CKpClfl-a reacts equally with (Y-, PI-, PII- and y-subspecies, and 
the antibodies CKpVlol-a, CKpVSflI-a and CKpVSPII-a react 
specifically with o-, flI- and PII-subspecies, respectively [7,8]. 
2.4. Immunocytochemical analysis 
Immunocytochemical staining of the leukemia-lymphoma 
cells was carried out as described in [15]. Cells were fixed with 
1% paraformaldehyde, cytocentrifuged onto glass slides and 
permeabilized with 0.3% Triton X-100. After incubation with 
1% Hz02 in methanol to block endogenous peroxidase, the cells 
were incubated with antibodies specific to the different PKC 
subspecies. Immunoreaction was visualized using the biotin- 
conjugated anti-rabbit antibody and streptavidin-conjugated 
peroxidase (Biogenex, CA) employing diaminobenzidine as 
substrate and observed under the light microscope. 
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Fig.1. Hydroxyapatite column chromatography of PKC from 
T-cell, B-cell and non-T/non-B cell leukemia-lymphoma cell 
lines. The PKC activity of these cell lines was separated by 
hydroxyapatite column chromatography and enzymatic activity 
was assayed as described in section 2. (A-C) PKC from T-cell 
leukemia-lymphoma cell lines, HPB-ALL, MOLT-3 and 
MOLT-15, respectively; (D-F) PKC from B-cell leukemia- 
lymphoma cell lines, NALM-6, U-698-M and RAMOS, 
respectively; (G) PKC from non-T/non-B cell leukemia- 
lymphoma cell line, KM-3; (O--O) PKC activity. 
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Fig.2. Hydroxyapatite column chromatography of PKC from 
myelomonocytic leukemia and erythroleukemia cell lines. The 
PKC activity of these cell lines were separated by hydroxyapatite 
column chromatography and enzymatic activity was assayed as 
described in section 2. (A-C) PKC from myelomonocytic 
leukemia cell lines, KG-l, ML-2 and HL-60, respectively; (D,E) 
PKC_ from erythroleukemia cell lines, SPI-802 and HEL, 
respectively; (+---o) PKC activity. 
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3. RESULTS 
3.1. Resolution of PKC subspecies 
The PKC of T-cell, B-cell and non-T/non-B cell 
leukemia-lymphoma cell lines was normally re- 
solved into two major peaks upon hydroxyapatite 
column chromatography (fig.1). The two enzyme 
peaks in HPB-ALL, MOLT-3, MOLT-15, 
NALM-6, U-698-M and KM-3 cells appeared at the 
concentrations of potassium phosphate that corre- 
spond to the elution positions of brain type II (P- 
sequence) and type III (a-sequence) PKC 
subspecies [4,5]. In general, T-cell lines contained 
more PKC than B-cell lines. RAMOS cells have 
type III but not type II PKC. On the other hand, 
MOLT-3 cells contain an additional small peak 
right after the peak of type III, the structure of 
which remains unknown (fig. 1B). 
In myelomonocytic leukemia cell lines, the two 
peaks of PKC were normally detected; KG-l, 
ML-2 and HL-60 cells contained enzymes cor- 
responding to type II and type III (fig.2). In KG-1 
and HL-60 cells additional peaks were found, the 
kinetic properties of which remain to be defined 
(fig.2A and C). 
In erythroleukemia cell lines, two enzyme peaks 
corresponding to type II and type III were also 
detected in SPI-802 cells (fig.2D). However, a 
single peak of PKC activity was detected in HEL 
cells, and this enzyme is apparently distinct from 
type II and type III, and appeared in the fractions 
46 to 50 (fig.2E). The PKC activity expressed in 
these human leukemia-lymphoma cell lines is sum- 
marized in table 1. The heterogeneity of PKC 
described above did not appear simply due to pro- 
teolytic artifacts during the purification proce- 
dures. All enzyme peaks were dependent on Ca’ + , 
phospholipid and diacylglycerol. 
3.2. Immunochemical analysis of PKC subspecies 
PKC subspecies expressed in T-cell leukemia- 
lymphoma cell lines were analyzed using antibodies 
specific to each PKC subspecies, as these cell lines 
contain large amounts of PKC as described above. 
Type II and type III PKC fractions of the T-cell 
leukemia-lymphoma cell lines reacted with the an- 
Table 1 






Non-T/non-B cell leukemia 
cell line 
Name Stage 
HPB-ALL T II 
MOLT-3 T III 
MOLT-15 T IV 
NALM-6 Pre B 











Specific activity (nmol/min per mg)’ 
















0.12 0.05f 0.03 
0.22 0.13 
0.03 0.02f 0.06 
Erythroleukemia SPI-802 
cell lines HEL 
a ALL, acute lymphoblastic leukemia 
b AMoL, acute monoblastic leukemia 
’ AML, acute myelomonocytic leukemia 
ALL 0.56 0.47 
Erythroleukemia 0.128 
d APL, acute promyelomonocytic leukemia 
e Protein kinase activity/mg protein in crude supernatant 
f Protein kinase activity appears in fractions 41 - 46 as shown in fig.ZA and C 
* Protein kinase activity appears in fractions 46 - 50 as shown in fig.ZE 
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tibody, CKpClfl-a, and showed an approximate 
molecular mass of 80 kDa (fig.3). This antibody 
recognizes a part of the amino acid sequence found 
almost commonly in rat brain type I (y-sequence), 
type II (@I- and PII-sequence) and type III (01- 
sequence) PKC. Most of the type II and type III 
PKC fractions of the other cell lines tested also 
showed similar 80 kDa band. Immunoblot analysis 
using antibodies CKpVSPI-a and CKpVSflII-a, 
which can distinguish the PI- and BII-sequence, in- 
dicated that the type II PKC fractions of T-cell 
leukemia-lymphoma cell lines contained predom- 
inantly the @II-subspecies, and only a small quanti- 
ty of the PI-subspecies. 
The expression of PKC subspecies in some 
human leukemia-lymphoma cell lines was in- 
vestigated further by immunocytochemical staining 
with polyclonal antibodies specific to the CY- and 
PII-sequence (fig.4). The staining was detected in 
the cytoplasm, although some membrane localiza- 
tion was noted within the T-cell leukemia- 
lymphoma cell lines, notably in MOLT-l 5. 
Fig.3. Immunoblot analysis of PKC fractions from T-cell 
leukemia-lymphoma cell lines. PKC fractions of hydroxyapatite 
column chromatography were subjected to immunoblot analysis 
using a polyclonal antibody, CKpClfi-a as described in section 2. 
(A, B) immunoblot analysis of type II and type III PKC 
fractions, respectively. Lanes: 1, PKC from rat brain; 2-4, PKC 
from T-cell leukemia-lymphoma cell lines, HPB-ALL, MOLT-3 
and MOLT-U, respectively. Arrow indicates the position of 
PKC. Molecular mass markers used are shown in kDa: 116, /8- 
galactosidase; 98, phosphorylase b; 68, bovine serum albumin; 
45, ovalbumin. 
Fig.4. Immunocytochemical staining of T-cell leukemia- 
lymphoma and non-T/non-B cell leukemia-lymphoma cell lines. 
T-cell leukemia-lymphoma cell lines, HPB-ALL, MOLT-3 and 
MOLT-15, and a non-T/non-B cell leukemia-lymphoma cell 
line, KM-3, were stained with polyclonal antibodies as described 
in section 2. (A, E) HPB-ALL cells; (B, F) MOLT-3 cells; (C, G) 
MOLT-15 cells; (D, H) KM-3 cells, respectively; (A-D) stained 
with the antibody CKpVlo-a; (E-H) stained with the antibody 
CKpVS@II-a, respectively. 
4. DISCUSSION 
PKC subspecies how tissue-specific expression 
[2,6-91. Type III (a-sequence) is distributed ubi- 
quitously in tissues and cell types so far examined, 
whereas type I (y-sequence) is found only in the 
central nervous tissue [6,8-lo]. In the present 
studies, most of the leukemia-lymphoma cell lines 
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are shown to co-express both type II and type III, 
and the ratio of these two subspecies greatly varies 
with the cell lines tested. The T-cell leukemia- 
lymphoma cell lines contained a larger amount of 
PKC activity than the non-T cells. At progressive 
stages in the preserved maturation of the T-cell 
leukemia-lymphoma cell lines, the type III enzyme 
activity was decreased. In contrast, the P-cell 
leukemia-lymphoma cell lines showed far less ac- 
tivity, and RAMOS cells had no type II enzyme. It 
has been reported that the RNA transcripts of both 
@I- and @II-subspecies are detected in rat spleen by 
in situ hybridization studies [ 171. Some of the dif- 
ferentiated B-cells may have both PI- and PII- 
subspecies. On the other hand, in myelomonocytic 
leukemia and erythroleukemia cell lines additional 
minor peaks were found, particularly in KG-l cells. 
The PKC in HEL cells, an erythroleukemia cell 
line, is distinct from both type II and type III PKC. 
It is possible that these enzymes are encoded by the 
cDNA clones of PKC, 6, E and r, recently iden- 
tified [18,19], although the precise correlation of 
these undefined peaks with the cDNA clones of 
PKC remains unknown. It has been reported that 
HL-60 cells, a myelomonocytic cell line, express 
PKC of type I, II and III [20], but the present study 
indicates that this cell line contains the type II and 
type III enzymes, and additionally an unidentified 
subspecies of PKC which is eluted in between. The 
detailed kinetic properties of this enzyme will be 
described elsewhere. 
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